The Leukemia Revolution: How Blood Cancer Helped Transform Modern Oncology

The history of blood cancer is, in many ways, the history of modern cancer medicine itself. From the earliest chemotherapy trials to monoclonal antibodies, targeted therapies, and precision medicine, many of oncology's most important advances were pioneered in leukemia and lymphoma. This presentation explores how discoveries in blood cancer reshaped the treatment of cancer as a whole and offers lessons for the future of medical innovation.

Modern CLL Management: Navigating a New Era of Precision Medicine

The treatment of chronic lymphocytic leukemia has changed more in the past two decades than in the previous century. This session examines how physicians now approach diagnosis, risk assessment, treatment selection, and long-term disease management, highlighting the scientific advances that have transformed outcomes for patients and the challenges that remain ahead.

BTK versus BCL2: Two Paths to Innovation and What They Teach Us About Drug Development

The development of BTK inhibitors and BCL2 inhibitors produced two of the most important therapeutic advances in hematologic oncology. Yet these drugs emerged through very different scientific pathways and faced distinct challenges on their road to success. This presentation examines the history of both approaches and explores broader lessons about innovation, risk, perseverance, clinical development, and the factors that determine whether a promising idea ultimately changes medical practice.

From Chlorambucil to Targeted Therapy: The Evolution of CLL Treatment

The story of CLL therapy reflects one of the most remarkable transformations in modern medicine. This presentation traces the journey from chemotherapy and watchful waiting to monoclonal antibodies, BTK inhibitors, BCL2 inhibitors, and emerging therapies. Along the way, it explores the scientific discoveries, clinical breakthroughs, and patient stories that helped redefine what is possible in cancer care.

What CLL Can Teach Us About the Future of Cancer Care

Few diseases illustrate the promise of precision medicine more clearly than CLL. By examining the evolution of CLL treatment, this presentation explores broader trends that are reshaping oncology, including biomarker-driven therapy, targeted drug development, personalized treatment selection, and the pursuit of increasingly durable remissions.